{"id":25535,"date":"2024-04-06T04:38:00","date_gmt":"2024-04-05T20:38:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=25535"},"modified":"2024-04-06T06:04:55","modified_gmt":"2024-04-05T22:04:55","slug":"jama%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9a%e5%b8%83%e5%9f%ba%e7%ba%b3%e6%b3%95%e7%b4%a2%e7%be%a4%e4%bd%93%e5%88%86%e5%8f%91%e9%98%bf%e5%a5%87%e9%9c%89%e7%b4%a0%e9%a2%84%e9%98%b2%e5%84%bf","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=25535","title":{"rendered":"[JAMA\u53d1\u8868\u8bba\u6587]\uff1a\u5e03\u57fa\u7eb3\u6cd5\u7d22\u7fa4\u4f53\u5206\u53d1\u963f\u5947\u9709\u7d20\u9884\u9632\u513f\u7ae5\u6b7b\u4ea1"},"content":{"rendered":"\n<p>Original Investigation&nbsp;<\/p>\n\n\n\n<p>February&nbsp;13,&nbsp;2024<\/p>\n\n\n\n<h1 class=\"wp-block-heading\">Mass Azithromycin Distribution to Prevent Child Mortality in Burkina Faso: The CHAT Randomized Clinical Trial<\/h1>\n\n\n\n<h3 class=\"wp-block-heading\">Catherine E.\u00a0Oldenburg,\u00a0Mamadou\u00a0Ouattara,\u00a0Mamadou\u00a0Bountogo,\u00a0et al<\/h3>\n\n\n\n<h3 class=\"wp-block-heading\"><em>JAMA.\u00a0<\/em>2024;331(6):482-490. doi:10.1001\/jama.2023.27393<\/h3>\n\n\n\n<p>Key Points<\/p>\n\n\n\n<p><strong>Question<\/strong>&nbsp;&nbsp;Does twice-annual mass azithromycin distribution prevent all-cause childhood mortality among children in Burkina Faso aged 1 to 59 months in the setting of seasonal malaria chemoprevention distribution?<\/p>\n\n\n\n<p><strong>Findings<\/strong>&nbsp;&nbsp;In this randomized trial of twice-yearly mass azithromycin distribution, 498 deaths were recorded over 60\u202f592 person-years (8.2 deaths\/1000 person-years) in the azithromycin group compared with 588 deaths over 58\u202f547 person-years (10.0 deaths\/1000 person-years) in the placebo group. The difference was not statistically significant.<\/p>\n\n\n\n<p><strong>Meaning<\/strong>&nbsp;&nbsp;Communities with mass azithromycin distribution had lower child mortality than controls, although the difference was not statistically significant. The study may have been underpowered to detect a clinically relevant difference.<a><\/a><\/p>\n\n\n\n<p>Abstract<\/p>\n\n\n\n<p><strong>Importance<\/strong>&nbsp;&nbsp;Repeated mass distribution of azithromycin has been shown to reduce childhood mortality by 14% in sub-Saharan Africa. However, the estimated effect varied by location, suggesting that the intervention may not be effective in different geographical areas, time periods, or conditions.<\/p>\n\n\n\n<p><strong>Objective<\/strong>&nbsp;&nbsp;To evaluate the efficacy of twice-yearly azithromycin to reduce mortality in children in the presence of seasonal malaria chemoprevention.<\/p>\n\n\n\n<p><strong>Design, Setting, and Participants<\/strong>&nbsp;&nbsp;This cluster randomized placebo-controlled trial evaluating the efficacy of single-dose azithromycin for prevention of all-cause childhood mortality included 341 communities in the Nouna district in rural northwestern Burkina Faso. Participants were children aged 1 to 59 months living in the study communities.<\/p>\n\n\n\n<p><strong>Interventions<\/strong>&nbsp;&nbsp;Communities were randomized in a 1:1 ratio to receive oral azithromycin or placebo distribution. Children aged 1 to 59 months were offered single-dose treatment twice yearly for 3 years (6 distributions) from August 2019 to February 2023.<\/p>\n\n\n\n<p><strong>Main Outcomes and Measures<\/strong>&nbsp;&nbsp;The primary outcome was all-cause childhood mortality, measured during a twice-yearly enumerative census.<\/p>\n\n\n\n<p><strong>Results<\/strong>\u00a0\u00a0A total of 34\u202f399 children (mean [SD] age, 25.2 [18] months) in the azithromycin group and 33\u202f847 children (mean [SD] age, 25.6 [18] months) in the placebo group were included. A mean (SD) of 90.1% (16.0%) of the censused children received the scheduled study drug in the azithromycin group and 89.8% (17.1%) received the scheduled study drug in the placebo group. In the azithromycin group, 498 deaths were recorded over 60\u202f592 person-years (8.2 deaths\/1000 person-years). In the placebo group, 588 deaths were recorded over 58\u202f547 person-years (10.0 deaths\/1000 person-years). The incidence rate ratio for mortality was 0.82 (95% CI, 0.67-1.02;\u00a0<em>P<\/em>\u2009=\u2009.07) in the azithromycin group compared with the placebo group. The incidence rate ratio was 0.99 (95% CI, 0.72-1.36) in those aged 1 to 11 months, 0.92 (95% CI, 0.67-1.27) in those aged 12 to 23 months, and 0.73 (95% CI, 0.57-0.94) in those aged 24 to 59 months.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.jamanetwork.com\/ama\/content_public\/journal\/jama\/939319\/joi230166va_1707775789.16707.png?Expires=1710877368&amp;Signature=uKYPFS35dMEyu8VLRkI3Yf5B-ZDGOnSTq2eVdBRH8JKh8JbxYD4tUgTrh~w-7wXEeU8NLIkdFEybXIBtVg7diTpNXGe3fVfwkrPWU8A-uUuJyZCckBkK-r~ChwdMUYm76tvScAE8frp~q27YCip9P51~kRPerDmQqDPmzpef7jHQ8Y-s64NyBGLPsSRum2Z03G1hVr~MjpArtfNnR9FGKanVggr5Te3X~tyQm9N5yerVJPTMDfw4MIucts4L7~~7XewDhUY69YqDObtqC-LGCmIr4f9Rb-NIWyraGTWphLKlNK5KZsbFOCi70YoNcwEB6AtaJmTvcrUu~zya5D9ESA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.jamanetwork.com\/ama\/content_public\/journal\/jama\/939319\/joi230166f1_1707775789.22471.png?Expires=1710877368&amp;Signature=NKzTI6k-sy5~zXFIvtRgzRzsYl1II5BvwE055K6Pfho9IItvRbBTowrKL5aOhOigYY0UyuBb6wezaEbuDgTkp689LwRTLXgG2fZkJHSEiQdT1xwqaThaBWehu8AI~lAgTvmPaSJ~T21Rl3ow702QAMe5MZ~NsEni8HZMrNvSSnKcEq1NS9J1wiipNCfEp5B5jPWIH5o3UwdW87Sq5w0sDQSr2RU7bAvZi04M97~i8sp-P4f~jozVUr5UkGDgG1fqxdye91jHhV3u9OirazzP87WzGd~ajpK-qX2p1BmKlAdBrVM9heXrPj-4TmpWZ3JmwOZIwfmH3a1gxVRTiBZ0tw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.jamanetwork.com\/ama\/content_public\/journal\/jama\/939319\/joi230166f2_1707775789.29836.png?Expires=1710877368&amp;Signature=TBWtU~adojsgTqaiDrkX7kaW6-BkMhnKdMitrktbOfdh-wuJF~fgcwtAIqGIl695pa7AvKhrAoiAgIBVfssqmAkQZjOKqtjKeJmvsuQM9zrXkS0HDlTtDDa9LXpfQry54Jrwy~Js2kytRJoqtQ5kTm2g3XktOxPp-KT4yxpURHSEOuhUTmFIU4mZkBGjWOviHlE6yV6STpuuIHfVDeSjnD93yLk6xRwycva88rTWoINkCyr97jx01unXySgz6gVOzWCDS5f11eteygzkHT2J6Yw2AeAfjQ0YQcmZMGo28PYvxxH9DUt7hglXk1OXCggSCFmnfqELFOdeym4dxrdu8g__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.jamanetwork.com\/ama\/content_public\/journal\/jama\/939319\/joi230166f3_1707775789.30836.png?Expires=1710877368&amp;Signature=SgS~FK9y1sDLhS8pVdONs09X9hcYXSRIESr2F-EuyC-bT1DOiWr4RLt7zxL5hEBnbXzXAC0jbjvqSKwTyprshCuzKLe-zzTh6-kx7rOqGAElQy~uLPtn8NEoBarHsykKNidKqHmjr70--QoFnhFOezfk8I5VjV9bEwjFpMzP7a3EWx0SO4HZSFiYkSvE~cIQCGOp3-P-7fOXXL6pScpFNjNEjYHdV2M-YGdtWXvLRLa8PELnMVkl6Po24KM9ODxwUCftqjSEakp8xYAbIk0Tb5abs-dWElx9svKPWwOJeSjvKo0LieKL-Wd7XX-M7WFh9cDoN6CQCogBWaMUDJDhYg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.jamanetwork.com\/ama\/content_public\/journal\/jama\/939319\/joi230166t1_1707775789.29336.png?Expires=1710877368&amp;Signature=LRyui1635O-cEoQHEshC5E1dvLwhfY2JF7rpybEsZrbbLY76xu1UbROm0palZchfaUh79bhoI4T-wbTYJzX7uPEI3zQwZ~YO3-2TPa47WBi1pomULzcRfUIGhp5s0orOa6oAhPWUy4gPTYF2UyEOU3jREwQRj72zXh~4xhJvYDP~pFrsQAGj5oegtKn41Bjr60jAaYlYqm-4OTd3CoZxqnGaAfNQvwJ4SV~OGE1gGTCuNdTvh1Cd0xY6342~fmCMIZmcFLXV4hyEuEnbF9h2VqMPuDZ6cpJ56TTnBhQIwH0jrQTtRX1CpYmNEREqMHtlkhq6wq3lC7yoUixYRqtoSg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\" alt=\"\"\/><\/figure>\n\n\n\n<p><strong>Conclusions and Relevance<\/strong>&nbsp;&nbsp;Mortality in children (aged 1-59 months) was lower with biannual mass azithromycin distribution in a setting in which seasonal malaria chemoprevention was also being distributed, but the difference was not statistically significant. The study may have been underpowered to detect a clinically relevant difference.<\/p>\n\n\n\n<p><strong>Trial Registration<\/strong>&nbsp;&nbsp;ClinicalTrials.gov Identifier:&nbsp;<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03676764\">NCT03676764<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Original Investigation&nbsp; February&nbsp;13,&nbsp;202 [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/25535"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25535"}],"version-history":[{"count":1,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/25535\/revisions"}],"predecessor-version":[{"id":25536,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/25535\/revisions\/25536"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25535"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25535"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}